Treatment for severe sepsis in adults launched
A new agent, drotrecogin alfa (Xigris), for the treatment of adult patients
with severe sepsis and multiple organ failure has been launched by Eli
Lilly (see p602).
Drotrecogin alfa is a recombinant version of the human activated protein
C molecule, a regulator of coagulation, and is indicated for use in addition
to best standard care, including adequate antibiotics and supportive treatment
(fluids, inotropes, vasopressors and support of failing organs, as required).
Activated protein C limits thrombin formation by inactivating Factors
Va and VIIIa, thereby providing negative feedback regulation of coagulation.
It is a modulator of the systemic response to infection and has both antithrombotic
and profibrinolytic properties. Drotrecogin alfa has similar properties
to those of human activated protein C.
|
